Prescription Drug Monitoring Programs (PDMP) / Prescription Monitoring Programs (PMP) are jurisdictionally operated electronic databases which, collect, maintain, and disseminate controlled substance prescription information specific to each jurisdiction’s laws and regulations. PDMP / PMPs are critical decision support tools that state officials, healthcare professionals, and law enforcement officers use to address prescription dug abuse, misuse, and diversion. PDMP and PMP are used interchangeably throughout this website as well as others.
In January 2019 NCPDP published NCPDP Standards-based Facilitator Model for PDMP-An Interoperable Framework for Patient Safety. In that paper, NCPDP provides their perspective on Prescription Drug Monitoring Programs (PDMPs) and a proposed solution. NASCSA reviewed this paper and created a document by several Prescription Monitoring Program (PMP) administrators and subject matter experts in response to the NCPDP publication to clarify and correct some of the statements and claims made by NCPDP and how existing PMPs address the opioid crisis, public health needs, and patient safety.
In December 2020 the NASCSA Executive Committee voted to have the PMP Committee to convene a workgroup with the PDMP Technical Training and Assistance Center to examine the reporting and processing of veterinary prescription dispensations. The workgroup consisted of PDMP representatives from Maryland, Massachusetts, Nebraska, New Hampshire, and South Carolina. This workgroup expanded upon a Veterinary Best Practices guide previously published by PDMP TTAC and performed an in-depth review, including surveys of state PMP administrators regarding veterinary prescription dispensing and reporting. Throughout 2021 NASCSA and the PDMP TTAC developed a document that discusses challenges, barriers, and opportunities for the dispensing and reporting of veterinary prescriptions and presents best practices.
State Prescription Monitoring Programs recently participated in a survey regarding which version of ASAP standards they were utilizing or planning to move to in the coming year. Attached please find the survey results.
ASAP Summary Survey 11/29/2021
Section 306 of the Controlled Substances Act (CSA) requires the Attorney General to establish production quotas for each basic class of controlled substances listed in schedules I and II, and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This function is delegated to the DEA. In March 2021, DEA sent a letter to NASCSA requesting assistance in obtaining PDMP data for the purpose of establishing its aggregate production quota, pursuant to 21 CFR 1303.11(b)(6). NASCSA, in collaboration with Bamboo Health, established a reporting framework that could be utilized by approximately 40 state, county, and territorial PDMPs. In an effort to encourage participation by all state PDMPs, Bamboo Health has provided a sample of the report and specifications for use by any state who wishes to help the DEA meet their statutory requirement. Please see the attachment for more information. Bamboo Health will provide assistance to states regarding questions related to report calculations and specifications. Please contact APQReport@BambooHealth.com. Thank you to all of the states who have assisted or plan to assist the DEA in fulfilling their obligation.
APQ Guidance JC 12/20/2021
This section features recent PMP press releases. The intent is to highlight a few programs at a time and is not meant to be a comprehensive list of all the PMPs in the news. If you would like to suggest a particular state / jurisdiction's recent PMP press release, please contact us.
Amid rising opioid overdose rates, State Senator Mattie Hunter (D-Chicago) proposes a new law to increase regulations for the prescription monitoring program (PMP). Senate Bill 1842 allows the PMP to send automatic reports to prescribers and dispensers when medication shopping is detected from five identifications of a prescriber or pharmacy in a six month period.
Press release dated 08/23/2021: [Click Here]
Governor Parson signs SB 63: Creating Statewide Prescription Drug Monitoring Program in Missouri.
Press release dated 06/07/2021: [Click Here]
Saint Louis County PDMP Enables Additional Enhancements for Heathcare Providers. The PDMP monitors the prescribing and dispensing of schedule II-IV controlled substances to assist in the identification and prevention of prescription drug misuse. The goals of this program are to improve controlled substance prescribing, inform clinical practice, and reduce medication misuse and overdose. The system sends Clinical Alerts to assist healthcare providers in identifying patients potentially at risk for overdose or addiction (substance use disorders).
Press release dated 10/20/20: [Click Here]
The New Jersey Prescription Monitoring Program (NJPMP), in partnership with the New Jersey Department of Human Services, announces $1.2 Million in funding obtained from the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) to implement NJPMP integration with electronic health records and pharmacy management systems across the state.
Press Release dated 8/31/20: [Click Here]
The Delaware Office of Controlled Substances (OCS) is pleased to announce a partnership with Appriss Health to provide interoperability services for all prescribers and pharmacists in Delaware. This service will enable providers to quickly and efficiently access PMP Aware and Narxcare data within their EHR, EMR, or pharmacy dispensing software through the PDMP Gateway® while minimizing interruptions to workflow and patient care. The project is funded by a grant from the Centers for Disease Control awarded to the Delaware Division of Public Health.
Press release dated 6/24/20: [Click Here]